News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
341,221 Results
Type
Article (20699)
Company Profile (116)
Press Release (320402)
Multimedia
Podcasts (112)
Webinars (5)
Section
Business (97211)
Career Advice (115)
Deals (15557)
Drug Delivery (77)
Drug Development (57813)
Employer Resources (30)
FDA (10034)
Job Trends (6455)
News (165487)
Policy (14113)
Tag
2027 BioCapital Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Standard (1)
2027 Genetown Standard (3)
2027 Pharm Country Standard (4)
Academia (1128)
Academic (1)
Accelerated approval (55)
ADA (37)
Adcomms (27)
Allergies (126)
Alliances (24782)
ALS (189)
Alzheimer's disease (1347)
Antibody-drug conjugate (ADC) (494)
Approvals (10452)
Artificial intelligence (421)
ASCO (290)
Autoimmune disease (329)
Automation (30)
Bankruptcy (92)
Best Places to Work (5823)
BIO (54)
BIOSECURE Act (13)
Biosimilars (183)
Biotechnology (87)
Bladder cancer (191)
Brain cancer (75)
Breast cancer (701)
Cancer (5539)
Cardiovascular disease (418)
Career advice (115)
Career pathing (6)
CAR-T (392)
CDC (12)
Celiac Disease (2)
Cell therapy (1082)
Cervical cancer (35)
Clinical research (52781)
Collaboration (1749)
Company closure (5)
Compensation (791)
Complete response letters (74)
COVID-19 (1235)
CRISPR (114)
C-suite (865)
Cystic fibrosis (141)
Data (7246)
Decentralized trials (1)
Denatured (16)
Depression (150)
Dermatology (77)
Diabetes (503)
Diagnostics (2543)
Digital health (30)
Diversity (2)
Diversity, equity & inclusion (6)
Drug discovery (255)
Drug pricing (98)
Drug shortages (21)
Duchenne muscular dystrophy (296)
Earnings (36083)
Editorial (33)
Employer branding (5)
Employer resources (29)
Events (55962)
Executive appointments (703)
FDA (13166)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (22)
Frontotemporal dementia (29)
Funding (1298)
Gene editing (244)
Generative AI (39)
Gene therapy (862)
GLP-1 (791)
Government (1796)
Grass and pollen (2)
Guidances (252)
Healthcare (9126)
Hematology (161)
HIV (66)
Huntington's disease (63)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (102)
Immunology and inflammation (253)
Immuno-oncology (100)
Indications (192)
Infectious disease (1421)
Inflammatory bowel disease (187)
Inflation Reduction Act (6)
Influenza (61)
Intellectual property (219)
Interviews (14)
IPO (7808)
IRA (20)
Job creations (940)
Job search strategy (97)
JPM (48)
Kidney cancer (16)
Labor market (26)
Layoffs (276)
Leadership (7)
Legal (2139)
Liver cancer (83)
Longevity (23)
Lung cancer (753)
Lymphoma (465)
Machine learning (35)
Management (7)
Manufacturing (804)
Marketing (2)
MASH (179)
Medical device (5446)
Medtech (5526)
Mergers & acquisitions (8638)
Metabolic disorders (1294)
mRNA (158)
Multiple sclerosis (171)
NASH (15)
Neurodegenerative disease (411)
Neuropsychiatric disorders (98)
Neuroscience (2733)
Neurotech (1)
NextGen: Class of 2026 (2468)
Non-profit (1412)
Now hiring (17)
Obesity (595)
Opinion (158)
Ovarian cancer (219)
Pain (202)
Pancreatic cancer (288)
Parkinson's disease (346)
Partnered (20)
Patents (432)
Patient recruitment (669)
Peanut (40)
People (25734)
Pharmaceutical (23)
Pharmacy benefit managers (13)
Phase 1 (16328)
Phase 2 (23600)
Phase 3 (17911)
Pipeline (7778)
Policy (165)
Postmarket research (1697)
Preclinical (6212)
Press Release (48)
Prostate cancer (299)
Psychedelics (67)
Radiopharmaceuticals (287)
Rare diseases (1117)
Real estate (2025)
Recruiting (15)
Regulatory (14658)
Reports (22)
Research institute (1348)
Resumes & cover letters (10)
Rett syndrome (44)
RNA editing (25)
RSV (38)
Schizophrenia (152)
Series A (241)
Series B (179)
Service/supplier (3)
Sickle cell disease (106)
Special edition (18)
Spinal muscular atrophy (150)
Sponsored (29)
Startups (1825)
Stomach cancer (16)
Supply chain (73)
Tariffs (37)
The Weekly (94)
Vaccines (466)
Venture capital (86)
Weight loss (360)
Women's health (64)
Worklife (1)
Date
Last 7 days (291)
Last 30 days (1334)
Last 365 days (21215)
2026 (11664)
2025 (20747)
2024 (22829)
2023 (24968)
2022 (31432)
2021 (32543)
2020 (28200)
2019 (20580)
2018 (15294)
2017 (16612)
2016 (14529)
2015 (17027)
2014 (11717)
2013 (9002)
2012 (9249)
2011 (9418)
2010 (8515)
Location
Africa (222)
Alabama (58)
Alaska (3)
Arizona (130)
Arkansas (6)
Asia (32384)
Australia (4688)
California (9316)
Canada (2235)
China (1411)
Colorado (299)
Connecticut (441)
Delaware (306)
Europe (51266)
Florida (1279)
Georgia (255)
Hawaii (2)
Idaho (22)
Illinois (632)
India (95)
Indiana (351)
Iowa (16)
Japan (537)
Kansas (70)
Kentucky (28)
Louisiana (37)
Maine (12)
Maryland (1082)
Massachusetts (7389)
Michigan (115)
Minnesota (424)
Mississippi (2)
Missouri (116)
Montana (11)
Nebraska (7)
Nevada (86)
New Hampshire (36)
New Jersey (2625)
New Mexico (16)
New York (2536)
North Carolina (1263)
North Dakota (10)
Northern California (4874)
Ohio (266)
Oklahoma (10)
Oregon (21)
Pennsylvania (1896)
Puerto Rico (9)
Rhode Island (22)
South America (301)
South Carolina (26)
Southern California (3562)
Tennessee (83)
Texas (1437)
United States (32886)
Utah (179)
Vermont (1)
Virginia (244)
Washington D.C. (38)
Washington State (852)
West Virginia (1)
Wisconsin (84)
341,221 Results for "immunovative therapies ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
May 20, 2026
·
15 min read
Press Releases
Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
April 2, 2026
·
5 min read
Press Releases
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
May 11, 2026
·
1 min read
Press Releases
Andelyn Biosciences and ENCell Co., Ltd Announce Strategic Partnership to Expand Global Reach of Gene Therapy Manufacturing
April 21, 2026
·
4 min read
Press Releases
Immunovant Announces Pricing of $550 Million Common Stock Financing
December 11, 2025
·
4 min read
Press Releases
Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
July 7, 2026
·
5 min read
Press Releases
Faron Pharmaceuticals Ltd: Grant of Options - July 1, 2026
July 1, 2026
·
5 min read
Press Releases
Faron Pharmaceuticals Ltd: Registration of Treasury Shares
June 11, 2026
·
2 min read
Press Releases
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
February 8, 2026
·
12 min read
Autoimmune disease
Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another
Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to focus on another next-gen asset for the indication.
March 19, 2025
·
1 min read
·
Annalee Armstrong
1 of 34,123
Next
